Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751027 | 0.84 | NPC1 (0.47) | PTGER1CYP2C9ALDH1A1CYP19A1MRGPRX4 | |
| SCHEMBL630152 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CYP19A1 | |
| SCHEMBL2574961 | 0.76 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL2888649 | 0.76 | ALDH1A1 (0.39) | PTGER1CYP2C9ALDH1A1MRGPRX4 | |
| SCHEMBL12980387 | 0.74 | PTGER1 (0.54) | PTGER1CYP2C9MRGPRX4 | |
| SCHEMBL3915942 | 0.73 | PTGER1 (0.58) | PTGER1CYP2C9CYP19A1MRGPRX4 | |
| SCHEMBL28085590 | 0.73 | PTGER1 (0.52) | PTGER1ALDH1A1MRGPRX4 | |
| SCHEMBL6295798 | 0.71 | MLYCD (0.48) | CYP2C9ALDH1A1 | |
| SCHEMBL7427088 | 0.71 | MLYCD (0.39) | ALDH1A1 | |
| SCHEMBL6980928 | 0.71 | MLYCD (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTGER1 1215/4885CYP2C9 3326/4885ALDH1A1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.